I-Mab Biopharma Clinches $65M to Propel Next-Generation Immuno-Oncology Therapy with Givastomig

I-Mab Biopharma, a U.S.-based global biotech company listed on NASDAQ (IMAB), has proudly announced a successful funding round, raising $65,000,000 to further accelerate its innovative work in precision immuno-oncology. This significant influx of capital is set to fuel the company's robust pipeline, particularly the development of givastomig—a potential best-in-class bispecific antibody designed to target Claudin 18.2-positive gastric cancers. Givastomig exemplifies I-Mab Biopharma’s groundbreaking approach, conditionally activating T cells via the 4-1BB signaling pathway within the tumor microenvironment where CLDN18.2 is expressed, thereby ensuring a focused and potent antitumor response while minimizing the toxicities typically associated with similar agents. This milestone funding will allow the company to accelerate clinical trials, further explore givastomig’s potential in treating first-line metastatic gastric cancers, and expand its evaluation into other solid tumors. In Phase 1 trials, givastomig demonstrated a strong tumor-binding property combined with significant antitumor activity, attributed to the synergistic interaction between CLDN18.2 and 4-1BB. Beyond laboratory and clinical achievements, I-Mab’s innovative trajectory was further underscored by the acceptance of new data related to givastomig for a Mini Oral presentation at the European Society of Medical Oncology Gastrointestinal Cancers Congress 2025, set to take place in Barcelona, Spain. This funding not only reinforces investor confidence but also marks a crucial step in I-Mab’s mission to deliver cutting-edge immunotherapy solutions, ultimately transforming patient outcomes in the battle against cancer.